Since M1 macrophages rely on cytoprotective mechanisms like Nrf2 activation to maintain their anti-tumor phenotype [20], it is not entirely surprising that treatment with the Nrf2 activator CDDO-Me during early stages alters macrophage polarization and has anti-tumor effects in vivo. This evidence concerns the gene NFE2L2 and neoplasm.